Qbic Fund

Qbic's pipeline originates almost exclusively from a consortium of Flemish knowledge partners — universities, research institutes, and teaching hospitals. The fund backs spin-offs and startups with formal R&D collaborations tied to these institutions. This creates a structured, not market-facing, origination model that gives Qbic early access to academic breakthroughs before they reach broader venture markets.

Qbic invests from pre-seed through growth stages. The firm is often the first institutional investor in a spin-off, using seed and early-stage equity to bridge the gap between laboratory discovery and commercial viability. Follow-on participation in later rounds is common for portfolio companies that achieve technical and clinical milestones.

The portfolio concentrates on hard-science and deep-tech verticals: digital health, biotechnology, AI and enterprise software, robotics, advanced materials, agritech, and photonics. Representative companies include MRM Health (microbiome therapeutics), eyeo (photonics for imaging), and AILOS Robotics (next-generation actuation).

The management team is led by Managing Partners Sofie Baeten, Steven Leuridan, and Cédric Van Nevel. Baeten and Leuridan hold PhDs in materials science and biomechanical engineering, respectively, while Van Nevel brings corporate venturing experience from Bekaert. Investment decisions draw on this combined technical and financial expertise, with PhD-level managers covering life sciences and engineering sectors.

Qbic operates through sequential fund vehicles — Qbic I, II, and III — each with a distinct vintage and investor base. The third fund was actively deploying capital as of 2024, including a pre-seed investment in Innocens. This multi-fund structure allows the firm to raise discrete pools of capital while maintaining continuity in its university-linked investment strategy.